167 related articles for article (PubMed ID: 16644573)
1. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck.
Henriksson E; Baldetorp B; Borg A; Kjellen E; Akervall J; Wennerberg J; Wahlberg P
Acta Oncol; 2006; 45(3):300-5. PubMed ID: 16644573
[TBL] [Abstract][Full Text] [Related]
2. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
4. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification.
Izzo JG; Papadimitrakopoulou VA; Li XQ; Ibarguen H; Lee JS; Ro JY; El-Naggar A; Hong WK; Hittelman WN
Oncogene; 1998 Nov; 17(18):2313-22. PubMed ID: 9811462
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
Kothari V; Mulherkar R
Anticancer Res; 2012 Jan; 32(1):121-8. PubMed ID: 22213296
[TBL] [Abstract][Full Text] [Related]
6. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck.
Farhadieh RD; Smee R; Rees CG; Salardini A; Eggleton S; Yang JL; Russell PJ
ANZ J Surg; 2009; 79(1-2):48-54. PubMed ID: 19183379
[TBL] [Abstract][Full Text] [Related]
8. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx.
Vielba R; Bilbao J; Ispizua A; Zabalza I; Alfaro J; Rezola R; Moreno E; Elorriaga J; Alonso I; Baroja A; de la Hoz C
Laryngoscope; 2003 Jan; 113(1):167-72. PubMed ID: 12514403
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.
Akervall J; Borg A; Dictor M; Jin C; Jin Y; Tanner M; Isola J; Mertens F; Wennerberg J
Int J Oncol; 2002 Jan; 20(1):45-52. PubMed ID: 11743641
[TBL] [Abstract][Full Text] [Related]
10. Amplification of the cyclin D1 gene is associated with tumour subsite, DNA non-diploidy and high S-phase fraction in squamous cell carcinoma of the head and neck.
Niméus E; Baldetorp B; Bendahl PO; Rennstam K; Wennerberg J; Akervall J; Fernö M
Oral Oncol; 2004 Jul; 40(6):624-9. PubMed ID: 15063391
[TBL] [Abstract][Full Text] [Related]
11. Image cytometry of cyclin D1: a prognostic marker for head and neck squamous cell carcinomas.
Liu SC; Zhang SY; Babb JS; Ridge JA; Klein-Szanto AJ
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):455-9. PubMed ID: 11352854
[TBL] [Abstract][Full Text] [Related]
12. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
Ishiguro R; Fujii M; Yamashita T; Tashiro M; Tomita T; Ogawa K; Kameyama K
Anticancer Res; 2003; 23(6D):5213-20. PubMed ID: 14981992
[TBL] [Abstract][Full Text] [Related]
13. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1.
Burnworth B; Arendt S; Muffler S; Steinkraus V; Bröcker EB; Birek C; Hartschuh W; Jauch A; Boukamp P
Eur J Cell Biol; 2007 Dec; 86(11-12):763-80. PubMed ID: 17198740
[TBL] [Abstract][Full Text] [Related]
14. A differential PCR system for the determination of CCND1 (cyclin D1) gene amplification in head and neck squamous cell carcinomas.
Schneeberger C; Eder S; Swoboda H; Ullrich R; Zeillinger R
Oral Oncol; 1998 Jul; 34(4):257-60. PubMed ID: 9813719
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
16. Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas.
Rodrigo JP; García-Carracedo D; García LA; Menéndez S; Allonca E; González MV; Fresno MF; Suárez C; García-Pedrero JM
J Pathol; 2009 Mar; 217(4):516-23. PubMed ID: 18991334
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitivity testing of xenografted squamous cell carcinomas of the head and neck region.
Elprana D; Kuijpers W; Wessels JM; Wagener DJ; van den Broek P
Anticancer Res; 1992; 12(6B):2229-39. PubMed ID: 1284201
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition effect on Tca8113/CDDP by antisense oligonucleotides of cyclin D1 combined with cis diamminedichloroplatinum].
Zhou XJ; Yu Y; Pan HY; Chen WT; Zhang P; Zhang ZY
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Jun; 41(6):354-7. PubMed ID: 16836906
[TBL] [Abstract][Full Text] [Related]
19. [In vitro gene silencing by siRNA of cyclin D1 on tongue squamous cell carcinoma cell line resistant to cisplatin].
Zhou XJ; Zhang ZY; Zhang P; Pan HY; Chen WT; Ye DX
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Nov; 41(11):646-9. PubMed ID: 17331354
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of the proliferative fraction and cyclin D1/CCND1 gene amplification in head and neck squamous cell carcinoma.
el-Naggar AK; Steck K; Batsakis JG
Cytometry; 1995 Sep; 21(1):47-51. PubMed ID: 8529470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
